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The effects of industry funding and positive
outcomes in the interpretation of clinical
trial results: a randomized trial among
Dutch psychiatrists
Joeri K. Tijdink1,2*, Yvo M. Smulders3, Lex M. Bouter1,4 and Christiaan H. Vinkers5
Abstract
Background: Most studies are inclined to report positive rather than negative or inconclusive results. It is
currently unknown how clinicians appraise the results of a randomized clinical trial. For example, how does the
study funding source influence the appraisal of an RCT, and do positive findings influence perceived credibility
and clinical relevance? This study investigates whether psychiatrists’ appraisal of a scientific abstract is influenced
by industry funding disclosures and a positive outcome.
Methods: Dutch psychiatrists were randomized to evaluate a scientific abstract describing a fictitious RCT for a
novel antipsychotic drug. Four different abstracts were created reporting either absence or presence of industry
funding disclosure as well as a positive or a negative outcome. Primary outcomes were the perceived credibility
and clinical relevance of the study results (10-point Likert scale). Secondary outcomes were the assessment of
methodological quality and interest in reading the full article.
Results: Three hundred ninety-five psychiatrists completed the survey (completion rate 45%). Industry funding
disclosure was found not to influence perceived credibility (Mean Difference MD 0.12; 95% CI − 0.28 to 0.47, p?)
nor interpretation of its clinical relevance (MD 0.14; 95% CI − 0.54 to 0.27, p?). A negative outcome was perceived
as more credible than a positive outcome (MD 0.81 points; 95% Confidence Interval (CI) 0.43 to 1.18, p?), but did
not affect clinical relevance scores (MD -0.14; 95% CI − 0.54 to 0.27).
Conclusions: In this study, industry funding disclosure was not associated with the perceived credibility nor
judgement of clinical relevance of a fictional RCT by psychiatrists. Positive study outcomes were found to be less
credible compared to negative outcomes, but industry funding had no significant effects. Psychiatrists may
underestimate the influence of funding sources on research results. The fact that physicians indicated negative
outcomes to be more credible may point to more awareness of existing publication bias in the scientific literature.
Keywords: Industry funding, Conflict of interest, Positive outcome bias, Credibility, Industry funding disclosure,
Psychiatrists, Methodological quality, Perceived credibility, Perceived clinical relevance
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Background
Several factors are known to influence the interpretation
of research findings by editors, reviewers, and scientists
[1–4]. Of these factors, study outcome and funding
disclosure are important [2, 5]. The excess of positive
results in the scientific literature, most likely due to
selective reporting, is widely acknowledged [6, 7]. In
addition, it has been firmly established that industry
sponsored studies more frequently report positive results
when compared to non-sponsored trials [8, 9], and that
‘negative’ industry-sponsored studies remain unpub-
lished [10–13]. However, a limited number of studies
have addressed factors that influence physicians in their
interpretation of the scientific literature. This topic is
important since physicians often fail to recognize the
impact of conflicts of interest [14], even though a critical
attitude by medical doctors towards industry funding
has been found to affect the perceived relevance of a
study [15]. In this context, psychiatry is a field of
particular interest. Psychiatrists are frequently criticized
for their ties to the pharmaceutical industry and the im-
pact of these ties has been intensely debated by top flight
journals [16–18]. Pharmaceutical companies have been
criticized for the high profits they received from antide-
pressants and antipsychotic sells. Their sells may have
been influenced by substantial publication bias [13].
Furthermore, a controversy has emerged from reanalysis
of data from sponsored study 329 that showed serious
side effects of antidepressants which were not reported
in the initial study [19]. Nevertheless, it is unknown
whether these and other factors such as study outcomes
and industry funding influence the scientific evaluation
of an RCT. If psychiatrists are easily swayed by funding
disclosure or positive outcomes, this could have direct
impact on their prescribing behavior and influence their
clinical decision making. Therefore, we aimed to assess
how study outcome and industry funding disclosure
influence psychiatrists’ perception of credibility and
clinical relevance of results of a hypothetical RCT.
Methods
Abstract development
Three of the authors of this study extensively discussed
the content of the proposed fictitious abstracts. We used
the PubMed format (reproduced without the NCBI logo
in Additional file 2: SF1–4) to make it appear like an
original study. After producing a first draft of the
abstracts by three authors, it was sent as a pilot version
to 5 other psychiatrists to receive feedback on formula-
tion, design, credibility and face-validity. This feedback
resulted in minor modifications and thus the final ver-
sion of the abstract. Each participant received the survey
in Dutch containing an abstract in the English language
describing an RCT for a non-existing novel antipsychotic
drug ‘vinquerine’ in a fictitious journal (“the ArXX
CXXX PsychXXX”). We chose to display the abstract in
English since Dutch psychiatrists are comfortable in
reading scientific literature in English. Four different
abstracts were created based on reported study outcome
(positive (a statistical significant difference compared
with olanzapine) vs negative (no statistical differences
compared with olanzapine)) and industry funding dis-
closure (yes/no). The original fake abstracts are included
in (Additional file 2: Figures SF1–4). The fictional study
compared the effects of the antipsychotic medication
vinquerine to those of olanzapine and placebo on psych-
otic symptoms in patients with a first-episode psychosis.
We chose olanzapine because it is an established and
often used treatment for psychosis. Severe side effects
were recorded in the fictitious abstract since these influ-
ence prescription behavior; the presence or absence of
side effects often makes significant influence on the
choices clinicians make in the treatment of psychiatric
patients.
A positive outcome was reported by showing a statisti-
cally and clinically significant effect of vinquerine compared
to olanzapine (an often applied first line treatment for
psychosis) and placebo. In the positive outcome abstract,
vinquerine was reported to have very limited side effects.
A negative outcome was reported as vinquerine and
olanzapine being equally effective, but vinquerine show-
ing important side effects. Both vinquerine and olanza-
pine were reported as being superior to placebo.
In the industry funded version, the second author was
reported to be a consultant for a fictional pharmaceut-
ical company (‘Olevy Pharmaceuticals’). We chose to put
the conflict of interest (CoI) under the second author,
rather than the first, since it was considered to be more
consistent with existing scientific reporting. At the
bottom of the fictitious industry funded abstracts, it was
clearly stated that ‘this study was funded by a research
grant from Olevy Pharmaceuticals’.
Identical methodological limitations were deliberately
introduced in all versions of the abstract to make it
consistent with Pubmed abstracts that, according to the
authors, were judged to be average quality. We felt that
reporting methods of average quality would make it
more likely that the article would be scrutinized for val-
idity. In contrast, a study without noticeable limitations
could be received by clinicians as being fabricated or
lacking veracity. The limitations of the fictitious abstract
included a relatively small sample size (n = 303), unclear
selection of study participants, non-blinded study design,
a relatively short follow-up period (4-weeks), and the
exclusion of non-compliant patients in a per-protocol
analysis. The abstract-only approach was deliberately
chosen since physicians frequently only read the abstract
of potentially interesting scientific studies [20].
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Statement: To prevent a potential confusion, we would
like to underline that the abstracts were invented.
Survey sample and randomization
VanDerHoef&Partners provided access to Dutch psychi-
atrists but were not involved in any part of the study
(concept, design, analysis, and writing). One thousand
five hundred sixty-six Dutch psychiatrists were random-
ized to receive an e-mail with a link to one of the follow-
ing four abstracts: 1) negative outcome/industry funding
disclosure, 2) negative outcome/no industry funding dis-
closure, 3) positive outcome/industry funding disclosure,
or 4) positive outcome/no industry funding disclosure.
The invitational e-mail and subsequent reminders were
sent in May and June 2014 and included a brief state-
ment to describe the goal of the study in very general
terms (‘to determine how psychiatrists evaluate scientific
research’). Participants were left unaware of the true
design and intention of the study. The e-mail included a
link to the online survey and the instructions on how-to
opt-out of this study if they so chose. Two reminders
were sent within a four week time frame to psychiatrists
who did not respond to the initial email. If psychiatrists
declined to respond, they were asked to follow an elec-
tronic link to a very brief online questionnaire to dis-
close their reasons for non-participation. Consent to
participate was implied by following the link to the
survey and completing the survey.
Survey characteristics and outcomes
Each abstract was accompanied by a short questionnaire
with 10 statements to determine the credibility (“How
would you rate the credibility of the abstract?”), clinical
relevance, methodological rigor (seven statements), and
interest in reading the full article using a 10-points
Likert scale (1: very poor, 10: extremely good). A control
question (“please enter the score 3 for this question”)
was included to check if participants did not randomly
complete the survey. Methodological rigor was assessed
with seven items, addressing different methodological
characteristics: study design, methodology, statistical
analysis, sample size, outcome measures, completeness
of reporting and overall study quality [see Additional file 1:
Table S1]. An equal-weighted sum score for the 7 items
was calculated. To prevent that the order of questions have
an undue influence on the answers respondents provided,
the primary outcome questions were randomly distributed
among the 10 questions.
After completion of the survey, participants’ attitudes
towards the pharmaceutical industry were assessed. We
also asked for financial ties with the pharmaceutical
industry. Participants were asked if they had received a
representative of a pharmaceutical company or if they
had received any industry funding in the past 6 months.
In addition, they were provided with four statements
regarding the influence of industry funding on scientific
clinical studies. Participants were asked to agree or
disagree. At this stage of the survey, participants were
not able to alter any of their previous answers.
Participant characteristics were obtained by asking
respondents to report their gender, age, professional
affiliations (academia, general hospital, or mental health
care facility) and whether or not they had obtained a
PhD. In addition, they were asked their place of resi-
dency, and whether the participant was actively involved
in scientific research. For the complete survey with all
the questions, see Additional file 3.
Statistical analysis
Primary outcome measures were the perceived credibil-
ity and the judgement regarding clinical relevance of the
study results reported in the fictitious abstract. Second-
ary outcomes were the level of interest in reading the
full article, and global assessment of methodological
rigor (sum score). All primary and secondary outcomes
were scored on a 10-point Likert scale. We checked for
distribution patterns of the primary and secondary out-
comes and concluded that the distribution allows the
use of ANOVA (see Additional file 1: Table S4). The
survey software was constructed in a manner that pre-
vented participants from submitting the survey unless all
questions were completed. This was done to minimize
missing data. First, possible interaction between the
industry funding disclosure and study outcome was ad-
dressed. For the primary outcomes, the effect of funding
disclosure and study outcome were analyzed using 2 × 2
ANOVA. Possible confounders and effect modifiers were
analyzed, including participants’ self-reported attitude
towards industry funding, and active relationships with
the pharmaceutical industry. As a secondary, exploratory
analysis, linear univariate and multivariate regression
analyses were used to identify other possible determi-
nants of perceived credibility and clinical relevance,
including demographic and job specific factors, and
active relations with industry. The Statistical Package for
the Social Sciences (SPSS) statistics (Chicago USA 2011,
version 20) was used for all statistical analyses.
Results
Participant characteristics
A total of 880 psychiatrists opened the invitation by
email, to which 580 psychiatrists responded (66%),
and 395 (45%) completed the full survey. Two re-
spondents were excluded because they failed to cor-
rectly answer the control question. Demographic data
and characteristics of the participants are presented in
Table 1. Attitudes towards industry funding are
included in Additional file 1: Tables S2 and S3).
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Industry funding disclosure and study outcome
Interaction analysis
No significant interaction was found between study out-
come in the abstract and mentioning of the industry fund-
ing disclosure, both on the primary outcome credibility
(p = 0.99) and the outcome clinical relevance (p = 0.41).
Industry funding disclosure does not affect credibility or
relevance assessments
Industry funding disclosure was not significantly associ-
ated with perceived credibility (MD 0.12; 95% CI − 0.28
to 0.47) nor clinical relevance (MD 0.14; 95% CI − 0.54
to 0.27). Likewise, no significant effects were found for
industry funding disclosure on the secondary outcomes
‘assessment of methodological rigor’ (MD 0.22; 95% CI
− 1.82 to 2.17), and ‘interest in reading the full article’
(MD 0.14; 95% CI − 0.40 to 0.71) (Table 2).
Positive study outcomes are perceived as less credible
A positive study outcome of the fictional RCT was asso-
ciated with significantly lower scores on credibility (MD
0.81; 95% CI 0.43 to 1.18) but not ‘clinical relevance’
Table 1 Demographic and professional characteristics of the participants
N = 395 %
Gender Male (%) 214 54
Age Mean (range) 50 (27–72)
Professional affiliation Academia 40 10
General Hospital 37 9
Mental Health Institution 248 63
Private Practice 63 16
Other 38 10
Residency background Academic Hospital 158 40
General Hospital 4 1
Mental Health Institution 200 51
Other 32 8
Sub-specialty Adult psychiatry 241 61
Child psychiatry 90 23
Geriatric psychiatry 25 6
Other 37 9
Received representative of a pharm. Company Yes 180 46
Received pharmacological funding Yes 14 4
Scientifically active Yes 131 33
PhD degree Yes 104 27
Years employed as psychiatrist (range) 14 (0–40)
Table 2 ANOVA analysis of the primary and secondary outcomes of the abstract with or without funding disclosure and with a
positive or negative study outcome
Funding (N = 206) No Funding (N = 187) Mean Difference (MD) 95% CI
Credibilitya 4.64 4.76 0.12 −0.28 to 0.47
Clinical relevance 5.30 5.16 0.14 −0.54 to 0.27
Interest in reading the full article 4.51 4.65 0.14 −0.40 to 0.71
Methodological quality (sum score)b 38.65 38.87 0.22 −1.82 to 2.17
Negative outcome (N = 200) Positive outcome (N = 193) Mean Difference (MD) 95% CI
Credibilitya 5.10 4.29 0.81 0.43 to 1.18
Clinical relevancea 5.16 5.30 0.14 −0.28 to 0.53
Interest in reading the full articlea 4.31 4.85 0.54 0.09 to 1.12
Methodological quality (sum score)b 5,63 5,44 0.19 −3.31 to 0.68
a10-point Likertscale score
bAverage score on a 10-point Likertscale of the seven individual items regarding methodological quality (see Additional file 1: Table S1)
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(MD 0.14; 95% CI − 0.28 to 0.53), compared to a nega-
tive study outcome. The secondary outcome ‘interest in
reading the full article’ (MD 0.54, 95% CI 0.09 to 1.12)
was statistically significant. The other outcome ‘assess-
ment of methodological rigor’ (MD 0.19; 95% CI − 3.31
to 0.68) was not significantly influenced by the reported
study outcome (Table 2).
No effect modification by relations with or attitude towards
industry funding
We investigated whether participants’ active relations
with- and attitude towards- industry were effect modi-
fiers or confounders in the observed relations between
study outcome and the primary outcomes. Both for
perceived credibility and clinical relevance, no interac-
tions or confounding were found for pharmaceutical
industry relations and attitude towards industry funding
(data not shown). Nevertheless, psychiatrists were well
aware of possible industry effects, with an average score
of 8.0 of 10 for the statement that “a pharmaceutical
company can influence study results”, a score of 7.4 out
of 10 for the statement that “funding has an effect on
the quality of research”, and 6.9 out of 10 for the state-
ment that “funding from a pharmaceutical company
has a negative influence on the validity of research
results” (see Additional file 1: Table S3).
Professional characteristics that influence perceived
credibility and clinical relevance
In a secondary exploratory analysis, we investigated
whether professional characteristics affect perceived
credibility and clinical relevance scores in the total study
population. Credibility of the RCT was negatively associ-
ated with having scientific experience (e.g. having a PhD
or being scientifically active) (MD -0.6; 95% CI − 0.99 to
− 0.21), and positively associated with having recently
received a pharmaceutical representative (MD 0.63; 95%
CI 0.25 to 1.01), funding from a pharmaceutical com-
pany (MD 1.27; 95% CI 0.25 to 2.30) or being employed
in a general mental health institution (MD 0.46; CI 0,06
to 0,85). Multivariate analyses of these variables did not
affect any of these results (data not shown).
Psychiatrists interpreted clinical relevance to be
lower if they had scientific experience (‘having a PhD’
or ‘being scientifically active’) (MD -0.43; 95% CI −
0.85 to − 0.02), were longer active as a psychiatrist
(beta − 0.02; 95% CI − 0.04 to 0.00) and had received
residency training in a general mental health institu-
tion rather than an academic hospital (MD 0.40; 95%
CI − 0.80 to 0.00). Multivariate analysis only showed
significant associations for scientific experience and
residency training in a general non-academic mental
health institution (data not shown).
Discussion
This study demonstrates that psychiatrists have more
confidence in the validity of a negative outcome than a
positive outcome of a fictitious study assessing a novel
antipsychotic drug. In apparent contrast, we did not find
a difference in the evaluation of a scientific abstract
when participants were displayed an industry funding
disclosure with the fictitious abstract. The reader’s atti-
tudes towards or relationships with the pharmaceutical
industry did not influence this analysis.
The relative distrust of a positive study outcome in
our study is in agreement with the recognition that
the medical literature suffers from positive outcome
bias [6, 7], particularly in drug studies [21, 22]. Posi-
tive outcome bias has also been convincingly demon-
strated in psychiatric literature, for example on the
effectiveness of antidepressants [4, 23] and antipsy-
chotics [24]. Presumably, respondents were aware of
this bias, generating hesitation to accept results that
may be considered ‘too good to be true’. The fact
that positive outcomes are more critically appraised
by psychiatrists is consistent with another study that
highlights the influence of positive outcomes in paper
acceptance rates in peer review [2]. These results are
not fully comparable as peer reviewers have other
criteria to assess a scientific paper than clinicians.
Although the effects of industry funding on study
outcomes has been well-established both in the
general medical literature [5] and in the psychiatric
literature [11], no effect was found for funding
disclosure on the credibility or perceived relevance of,
in particular the positive outcome version of the
abstract. Moreover, participants’ attitudes towards
pharmaceutical industry funding did not influence
participants’ appraisal of the fictitious abstract. (see
Additional file 1: Table S3). Participants with overall
high scores on statements that pharmaceutical com-
panies can unduly influence study results were no
more likely to question the validity of the fictitious
abstract, even though the abstract clearly disclosed
the funding. We cannot infer why these attitudes did
not affect the results of our study. Apparently, psychi-
atrists did not automatically connect their perception
of funding effects to the actual interpretation of the
abstract we sent them. It may well be that respon-
dents account for the mentioned disclosures, and may
think that their knowledge will not influence the
perception of research results.
Disclosure of industry funding in itself does not make
study results more or less valid [25]. Future research
should investigate whether funding disclosures on scien-
tific abstracts are warranted. One might argue that
reporting industry disclosures could unjustifiable influ-
ence the perceived credibility of research results simply
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because it was funded by or carried out by the pharma-
ceutical industry.
The recent media attention on study 329 regarding
antidepressant drugs reinforces the need for individual
patient data and original study protocols to increase the
validity of scientific results as registration of clinical
trials is insufficient [19].
Participants were a random sample from ±3500
Dutch psychiatrists. Nevertheless, around 27% of the
participants had a PhD degree, which is higher than
the average among community psychiatrists. Probably,
psychiatrists with a PhD are more likely to participate
in our survey, as they would feel more competent to
assess a scientific abstract. Moreover, in light of the
response rate of 45%, we checked whether the study
results are generalizable to the total population of
Dutch psychiatrists. With 54% of the survey sample
being male compared to 59% in another recent study
of Dutch psychiatrists, [26], there is no reason to
assume that the results are not generalizable.
Secondary analyses showed that credibility scores
were higher in psychiatrists with active relations with
pharmaceutical companies and this was independent
of industry funding disclosure. Credibility scores of
the fictitious abstract were lower for the psychiatrists
with scientific research experience. These results
suggest that participants’ relationships with the
pharmaceutical industry can influence study appraisal
in a more positive or less critical manner.
To our knowledge, this is the first randomized study
to investigate whether industry funding disclosure and
study outcomes can influence the opinion of psychia-
trists on the credibility and relevance of clinical research.
In contrast, a somewhat smaller, previous study among
269 internists suggested that industry funding disclosure
resulted in lower scores on methodological rigor and less
confidence in the results [15]. The study design with
different methodological approaches and the inclusion
of three hypothetical drugs may have played a role in the
discrepancy between these two studies. Additionally, it
may be possible that internists are more critical towards
pharmaceutical industry funded studies compared to
psychiatrists.
The results of this study should be cautiously inter-
preted in light of several limitations. First, internet-based
questionnaires can suffer from a selective response bias,
predominantly attracting participants who feel capable
of assessing a scientific abstract. In our study, the re-
sponse rate of 45% was relatively high compared to other
internet-based surveys for physicians [27, 28]. To calcu-
late the response rate, we used the psychiatrists who
opened the email as the denominator. A stricter calcula-
tion of the response rate would use all invitees (n =
1566) - whether they opened the email or not - in our
response rate determination. This would have resulted
in a response rate of 25% (395 out of 1566 invitations).
We did not survey reasons for non-response. Most
likely, psychiatrists lack time and energy to engage in
online surveys. Non-response could also be due to the
topic of the survey. Possibly, some psychiatrists might
have been reluctant to participate as they could feel not
competent enough to judge a scientific abstract on its
quality.
Second, a 19% difference (Cohen’s d 0.43) in perceived
credibility score and the 13% difference (Cohen’s d 0.19)
in interest in reading the full article between the two
groups is large enough to allow firm conclusions. Third,
we did not find a significant difference between funding
disclosure and perceived credibility. Although it may be
enticing to conclude that there is no relation between
the two variables, we cannot draw this conclusion from
our data as no evidence of an association is not evidence
of no association. Fourth, it might be that the partici-
pants perceived the positive study as invalid because
olanzapine is a well-established reference antipsychotic
drug. Furthermore, they might have perceived the
negative study as more realistic in terms of symptom
reduction. Fifth, the side effect profile was different in
the positive outcome abstract compared to the negative
outcome abstract. This was done intentionally to assure
that the positive outcome abstract would be perceived as
a positive study. However, this may have had a collateral
effect on the perceived credibility. Reporting severe side
effects might improve the intuitive credibility of an
abstract as psychiatrists frequently discuss side effects
with patients and are focused on side effects in their
treatments.
Finally, the question remains if the responders did no-
tice the presence of the disclosure of industry funding.
Some respondents may not have noticed the disclosure
of industry funding in the scientific abstract, even
though all seven psychiatrists who pretested the
fictitious abstract noticed it. Participants may also have
assumed that the study on a novel antipsychotic would
automatically be funded by industry even without an
explicit disclosure statement.
Conclusion
In this randomized study among psychiatrists, the effect
of industry funding disclosure was not associated with
the reliability and relevance of the results of a random-
ized clinical trial for a fictitious antipsychotic drug. In
contrast, psychiatrists more critically interpreted the ab-
stract of the RCT when a positive outcome was reported.
Our results are timely in light of the recent discussion
on the effects of industry-physician relations in several
leading medical journals [16, 17, 29]. There is a striking
discrepancy between psychiatrists’ attitudes towards the
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pharmaceutical industry and the effects that funding dis-
closure has on their perceived credibility and judgement
of clinical relevance of the RCT.
Nevertheless, the credibility of the RCT was lower in
psychiatrists with more scientific experience and higher
when psychiatrists received a pharmaceutical representa-
tive or received funding from a pharmaceutical com-
pany. Future research could investigate whether explicit
funding disclosures on scientific abstracts in databases
such as warranted.
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